Ramjet--Just to amplify your point, we don't know the dose that the 11 responders took. If there is a significant dose-response relationship, and the average ORR of both cohorts is 17.2%, then by definition, the 700mg dose will reveal a better ORR percentage. Given this kind of logic, the ORR of the 700mg dose should creep or leap into the 20% range... And when you add the maturation of the data, as 12345 pointed out in an earlier post, we could even get into the 30% range or beyond.
Take another look at the poster... The 3 patients with 100, 99, and 98 percent ctDNA declines were all from the 350 cohort. I'm going to go out on a limb here and suggest at least a couple of these these patients are at least Partial Responders. I don't have a calculator, and I don't want to do the math by hand, but if that is the case, then the ORR percentage of the 700mg cohort is already over 20%... (if the numbers hold).
11 patients in the poster had 90% or better ctDNA clearance, and there are 11 potential responders being adjudicated. That could be just a coincidence... or it could indicate that both dose and length of time on the drugs drive clinical responses. As the trial matures, both of these factors should work in our favor. Or--am I missing something here?
Right now we know that 8 out of the 11 with ctDNA declines greater than 90% were on 700mg of leronlimab. And yet those with the most significant declines, as noted, were the 3 from the 350mg cohort. This suggests to me that the Clover trial has more surprises for us before all is said and done. But it looks to me like all these surprises will be to the upside. The ORR of the 700mg dose of leronlimab isn't the Primary Endpoint of the trial... but you can bet that is the number that potential partners will notice. And Hoffman will run with.
Along with an increase in PD-L1 numbers. Which we haven't even discussed yet.
Take another look at the poster... The 3 patients with 100, 99, and 98 percent ctDNA declines were all from the 350 cohort. I'm going to go out on a limb here and suggest at least a couple of these these patients are at least Partial Responders. I don't have a calculator, and I don't want to do the math by hand, but if that is the case, then the ORR percentage of the 700mg cohort is already over 20%... (if the numbers hold).
11 patients in the poster had 90% or better ctDNA clearance, and there are 11 potential responders being adjudicated. That could be just a coincidence... or it could indicate that both dose and length of time on the drugs drive clinical responses. As the trial matures, both of these factors should work in our favor. Or--am I missing something here?
Right now we know that 8 out of the 11 with ctDNA declines greater than 90% were on 700mg of leronlimab. And yet those with the most significant declines, as noted, were the 3 from the 350mg cohort. This suggests to me that the Clover trial has more surprises for us before all is said and done. But it looks to me like all these surprises will be to the upside. The ORR of the 700mg dose of leronlimab isn't the Primary Endpoint of the trial... but you can bet that is the number that potential partners will notice. And Hoffman will run with.
Along with an increase in PD-L1 numbers. Which we haven't even discussed yet.
8
